Loading
Cardiac Imaging and Diagnostics / Lung Cancer Research Studies / Chemotherapy-induced Cardiotoxicity and Mitigation · Journal article
Current Cardiology Reports · September 4, 2026
A consensus or society position rather than new primary data.
This narrative review examines circulating biomarkers for risk stratification and prognostication in cancer therapy-related cardiovascular toxicity. Cardiac troponins show strong prognostic value and natriuretic peptides show variable performance; emerging biomarkers (sST2, galectin-3, MPO, microRNAs) demonstrate early promise but lack standardization and clinical validation. The review emphasizes that no single biomarker is sufficient and recommends multimodal strategies integrating biomarkers, imaging, and clinical assessment, with acknowledgement that prospective validation of these integrated approaches remains needed.
Narrative review. Patients undergoing cancer therapy at risk for cardiovascular toxicity in cardio-oncology clinical settings.
Cardiac troponins demonstrate consistently strong prognostic value for cardiotoxicity Natriuretic peptides show variable predictive performance for cardiotoxicity Emerging biomarkers (sST2, galectin-3, MPO, inflammatory markers, circulating microRNAs) show early promise for detecting subclinical injury but lack standardization and validation for routine clinical use
Cardiac troponins demonstrate consistently strong prognostic value for cardiotoxicity Natriuretic peptides show variable predictive performance for cardiotoxicity
Clinicians should recognize that troponins offer stronger prognostic information than natriuretic peptides for cardiotoxicity risk, but no single biomarker suffices for clinical decision-making. A multimodal approach integrating biomarkers with imaging (particularly GLS) and clinical context is increasingly recommended, though standardized protocols and prospective validation of these combined strategies remain incomplete.
A narrative review synthesizing current evidence on circulating biomarkers in cardio-oncology, recommending multimodal assessment strategies but acknowledging gaps in validation and standardization rather than reporting new primary data.
As stated by the source record.
Clinicians should recognize that troponins offer stronger prognostic information than natriuretic peptides for cardiotoxicity risk, but no single biomarker suffices for clinical decision-making. A multimodal approach integrating biomarkers with imaging (particularly GLS) and clinical context is increasingly recommended, though standardized protocols and prospective validation of these combined strategies remain incomplete.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
PURPOSE OF REVIEW: Circulating biomarkers are increasingly utilized in cardio-oncology for risk stratification, early detection, and prognostication of cancer therapy-related cardiovascular toxicity. This review summarizes the current evidence supporting established and emerging biomarkers, with a focus on their clinical utility and limitations. RECENT FINDINGS: Cardiac troponins and natriuretic peptides remain the most widely studied biomarkers, with troponins demonstrating consistently strong prognostic value and natriuretic peptides showing more variable predictive performance for cardiotoxicity. Emerging data highlight limitations in biomarker-guided therapeutic strategies, with inconsistent evidence for improved clinical outcomes. Novel biomarkers, including soluble suppression of tumorigenicity 2 (sST2), galectin-3, myeloperoxidase (MPO), inflammatory markers, and circulating microRNAs, show early promise for detecting subclinical injury through distinct pathophysiological pathways but lack standardization and validation for routine clinical use. Imaging biomarkers, including global longitudinal strain (GLS) and cardiac MRI parametric mapping, complement circulating markers and are increasingly integrated into surveillance strategies, with emerging randomized evidence supporting GLS-guided cardio-protection. Increasing emphasis has been placed on multimarker approaches and their integration with imaging and clinical context to improve diagnostic accuracy, although prospective validation of these strategies remains needed. Circulating biomarkers play an increasingly important role in contemporary cardio-oncology practice; however, no single biomarker is sufficient to guide management across all clinical scenarios. A multimodal strategy incorporating biomarkers, imaging, and clinical assessment is increasingly recommended. Future research should focus on standardization, validation of emerging biomarkers, and defining the role of biomarker-guided interventions to improve cardiovascular and cancer outcomes.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.